Wells Fargo’s Galmed Pharmaceuticals GLMD Stock Holding History

Wells Fargo’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24	Hold	5	–	–	﹤0.01%	6894
2026 Q1	$21	Buy	5 +4	+400%	+$22	﹤0.01%	6786
2025 Q4	$7	Hold	1	–	–	﹤0.01%	6928
2025 Q3	$12	Hold	1	–	–	﹤0.01%	6808
2025 Q2	$17	Hold	1	–	–	﹤0.01%	6814
2025 Q1	$13	Sell	1 -1	-50%	-$20	﹤0.01%	6743
2024 Q4	$57	Hold	2	–	–	﹤0.01%	6483
2024 Q3	$123	Hold	2	–	–	﹤0.01%	6260
2024 Q2	$56	Hold	2	–	–	﹤0.01%	6302
2024 Q1	$71	Hold	2	–	–	﹤0.01%	6740
2023 Q4	$93	Hold	2	–	–	﹤0.01%	6790
2023 Q3	$126	Hold	2	–	–	﹤0.01%	6700
2023 Q2	$610	Hold	2	–	–	﹤0.01%	6446
2023 Q1	$1.3K	Hold	2	–	–	﹤0.01%	6309
2022 Q4	$1.52K	Sell	2 -1	-33%	-$524	﹤0.01%	6075
2022 Q3	$1K	Sell	3 -1	-25%	-$683	﹤0.01%	6345
2022 Q2	$4K	Hold	4	–	–	﹤0.01%	6085
2022 Q1	$10K	Hold	4	–	–	﹤0.01%	6265
2021 Q4	$12K	Hold	4	–	–	﹤0.01%	6480
2021 Q3	$18K	Hold	4	–	–	﹤0.01%	6007
2021 Q2	$19K	Hold	4	–	–	﹤0.01%	5921
2021 Q1	$21K	Hold	4	–	–	﹤0.01%	6132
2020 Q4	$20K	Hold	4	–	–	﹤0.01%	5855
2020 Q3	$23K	Hold	4	–	–	﹤0.01%	5718
2020 Q2	$30K	Hold	4	–	–	﹤0.01%	5609
2020 Q1	$21K	Hold	4	–	–	﹤0.01%	5584
2019 Q4	$37K	Buy	4 +3	+300%	+$20.6K	﹤0.01%	5600
2019 Q3	$5K	Hold	1	–	–	﹤0.01%	6059
2019 Q2	$8K	Sell	1 -1	-50%	-$10.3K	﹤0.01%	5953
2019 Q1	$25K	Buy	2 +1	+100%	+$11.6K	﹤0.01%	5476
2018 Q4	$14K	Sell	1 -14	-93%	-$196K	﹤0.01%	5857
2018 Q3	$297K	Buy	+15	New	+$281K	﹤0.01%	4781
2017 Q2	–	Sell	-3	Closed	-$24K	–	6305
2017 Q1	$24K	Hold	3	–	–	﹤0.01%	5665
2016 Q4	$18K	Sell	3 -2	-40%	-$10.6K	﹤0.01%	5657
2016 Q3	$33K	Buy	+5	New	+$30.2K	﹤0.01%	5450
2015 Q3	–	Sell	-1	Closed	-$20K	–	6288
2015 Q2	$20K	Hold	1	–	–	﹤0.01%	5595
2015 Q1	$19K	Sell	1 -1	-50%	-$12K	﹤0.01%	5401
2014 Q4	$14K	Sell	2 -80	-98%	-$695K	﹤0.01%	5498
2014 Q3	$1.02M	Buy	+82	New	+$897K	﹤0.01%	3454

Other funds holding GLMD

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's GLMD Position: Q2 2026 in Review

Wells Fargo held its Galmed Pharmaceuticals (GLMD) position steady in Q2 2026 at 5 shares worth $24. The position accounts for ﹤0.01% of the portfolio, ranked #6894.

Wells Fargo first reported a position in GLMD in Q3 2014 and has held it in 39 quarters since. The position peaked at $1.02M in Q3 2014. 11 funds tracked by Wall St. Rank hold GLMD as of Q2 2026.

Wells Fargo held 5 shares of Galmed Pharmaceuticals worth $24 as of Q2 2026.
Wells Fargo left its Galmed Pharmaceuticals share count unchanged in Q2 2026.
Galmed Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6894 holding.
Wells Fargo first reported a position in Galmed Pharmaceuticals in Q3 2014 and has held it in 39 quarters since.
Wells Fargo's Galmed Pharmaceuticals position peaked at $1.02M in Q3 2014.
11 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.